LDN is believed to function as a short-acting, transient opioid receptor antagonist. This brief blockade signals the body to increase its own production of endogenous opioids (endorphins and enkephalins) and up-regulate opioid receptors. This compensatory increase in natural opioids is hypothesized to regulate immune function, reduce chronic inflammation, and enhance feelings of well-being.